Neuropathix

Use of the Dual-action Neuroprotective Compound KLS-13019 to Treat Motor Impairment in a Preclinical Model of Parkinson’s Disease Study Rationale: Parkinson’s disease (PD) is associated with a loss of mitochondrial function and increased inflammation. A dual-action drug candidate, KLS-13019, both protects mitochondria from chemical stress and displays anti-inflammatory properties in cells and in rodents that develop a PD-lik...

Dean Petkanas, CEO of Neuropathix and Kannalife Sciences interviewed from I am Biotech Convention - a dive deep into the groundbreaking work Kannalife is doing in the field of cannabinoid-based pharmaceuticals, particularly efforts in developing treatments for chemotherapy-induced peripheral neuropathy.

Exploring Neuroprotective Drugs with Dean Petkanas CEO of Kannalife Sciences In this episode of the Life Science Success Podcast, Dean Petkanas, co-founder of Kannalife Sciences, is interviewed at the Bio International Convention in S...

🎉 We're thrilled to share some exciting news! Neuropathix Kannalife Sciences, Inc. has been chosen by the National Institutes of Health (NIH) as one of the 30 NIH SEED Companies to present at the prestigious I am Biotech International Convention in San Diego. Mark your calendars for our CEO Dean Petkanas's presentation on Tuesday, June 4, 2024, at 4:30 PM in Company Presentation Theater 3. Plus, swing by the NIH booth #825 on Tuesday, June 4, 2024, at 11:56 AM for an up-close look.

A big thank you to NIH for recognizing our team's dedication to researching treatments for unmet medical needs.

Dean Petkanas Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

🔬 New Research Alert! Neuropathix, Kannalife Sciences - Scientists uncover a link between KLS-13019 and the GPR55 receptor, shedding light on its promising role in reducing inflammatory markers associated with chemotherapy-induced peripheral neuropathy (CIPN). In contrast, cannabidiol (CBD) shows low efficacy, highlighting significant differences between the two compounds.

Our recent study in the Journal of Molecular Neuroscience investigates the anti-inflammatory actions of KLS-13019 and CBD in CIPN.

💡 Insights from this study pave the way for targeted therapies and innovative approaches to treating inflammation. Stay tuned.

📚 Read the full study here: https://rdcu.be/dFqru

rdcu.be